Company intelligence / Profile preview
Sangamo Therapeutics
- Ownership
- Public · SGMO
- Employees
- ~354
- Development stage
- Other
Overview
Sangamo is a pioneer in genomic medicine using proprietary zinc finger technology platforms. Its lead wholly owned programs target serious neurological and rare genetic diseases. The company has advanced its neurology pipeline toward the clinic and secured major licensing deals with Genentech and Astellas for novel capsid delivery technologies. The Fabry disease program is on an accelerated regulatory path after positive Phase I/II data; a pivotal BLA submission is anticipated in the second half of 2025. An IND was cleared for ST‑503 in iSFN pain with first patient dosing expected mid‑2025. Nonclinical proof-of-concept was demonstrated in prion disease models.[6][8]
- Therapeutic areas
- HematologyRare DiseasesNeurology
- Modalities
- Gene therapy (AAV-based gene transfer)Genome editing (Zinc Finger Nucleases - ZFN)Epigenetic regulation (Zinc Finger Protein Transcription Factors - ZFP-TF)
- Industry
- Biotech
Drug pipeline
34 assets33 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sangamo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sangamo Therapeutics.